[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-volunteers-only\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-volunteers-only":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,66,96,145,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100589304","study-on-multi-modality-models-of-cardiac-function-in-healthy-individuals-100589304",false,"NCT06952673","Study on Multi-Modality Models of Cardiac Function in Healthy Individuals","Study on the 'Seismocardiography-Electrocardiography' Coupling Dynamics and Its Exercise-load Reactivity Model in Healthy Individuals","Inclusion Criteria:\n\n* Age 18-60 years\n* Healthy individuals with no significant medical history\n* Signed informed consent as an acceptance to participate to the trial\n\nExclusion Criteria:\n\n* History of severe cardiovascular, cerebrovascular, pulmonary, hepatic, renal, psychiatric, or other critical systemic disorders\n* Peripheral vascular diseases, musculoskeletal disorders, or other conditions limiting physical mobility\n* Uncontrolled hypertension (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg)\n* History of anemia\n* Moderate to severe obesity (BMI ≥32.5 kg\u002Fm²)\n* Pregnant or lactating women\n* Any other conditions deemed ineligible for participation per investigator's discretion",true,"ALL","18 Years","60 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this study, wearable multi-modal microsensors were deployed to simultaneously capture seismocardiography (SCG) and electrocardiography (ECG) signals, delineating the exercise-load-dependent responsiveness of SCG-ECG dynamic coupling during graded-speed treadmill protocols.",[28],"Healthy Volunteers Only",[30],"Seismocardiography, ECG, Exercise Responsivity","RECRUITING","2026-04-22",{"date":34,"type":35},"2026-04-28","ACTUAL",{"date":37,"type":35},"2025-04-25",{"date":39,"type":22},"2026-12-31",{"name":41,"class":42},"Shanghai Ruiwei Digital Technology Co. Ltd.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":65},"100586600","phase-1-a-study-to-assess-the-safety-and-effects-of-the-investigational-drug-bw-40202-in-healthy-volunteers-100586600","NCT06917482","A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-40202 in Healthy Subjects","Key inclusion criteria:\n\n1. Must have given written informed consent and be able to comply with all study requirements.\n2. Males or females aged 18 to 60 years old, inclusive, at the time of informed consent.\n3. BMI ≥18 and ≤32 kg\u002Fm2 with 50 kg \\\u003Cbody weight ≤100 kg.\n\nKey exclusion criteria:\n\n1. Any clinically significant chronic medical condition or clinically significant abnormality in laboratory parameters that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.\n2. Hospitalization for any reason within 60 days prior to screening.\n3. Any clinically significant acute condition such as fever (\\>38 degree centigrade) or acute respiratory illness within 14 days of study drug administration.\n4. Systolic blood pressure (more than equal to) 140 mmHg and\u002For diastolic blood pressure (more than equal to) 90 mmHg after at least 5 minutes resting (seated or supine) at screening and Day -1(Repeat blood pressure measurement will be allowed at the discretion of the investigator).\n5. Any liver function panel analyte value \\> 1.2 × upper limits of normal (ULN) which includes aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin (TBIL), alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) at screening.\n6. International normalized ratio (INR) above 1.2 × ULN at screening or Day -1.\n7. Single 12-lead electrocardiogram (ECG) with clinically significant abnormalities at screening or Day -1, asdetermined by the clinical investigator.\n8. History or clinical evidence of alcohol abuse,\n9. History or clinical evidence of drug abuse, within the 12 months before screening.\n10. Donated or lost \\>200 mL of blood within 30 days prior to screening.",{"count":52,"type":22},40,[54],"PHASE1","This study will test the safety of a new drug called BW-40202 in healthy adults. The drug is a clear liquid given as an injection under the skin (subcutaneous injection). The study will test five different doses of BW-40202 compared to a placebo (saltwater solution).\n\nParticipants will be divided into five groups, with each group receiving a different dose of BW-40202 or placebo. In each group, eight people will be randomly assigned to receive either the drug (6 people) or placebo (2 people).\n\nThe Safety Review Committee will review the safety data before increasing the dose for the next group.\n\nStudy nurses or trained staff will give the injections. Pharmacy staff will keep records of how much drug each participant receives, any returned or destroyed doses, and any changes from the planned dosing schedule. These records will be securely stored and available for review.",[28],"2025-07-22",{"date":59,"type":35},"2025-07-25",{"date":61,"type":35},"2025-06-30",{"date":39,"type":22},{"name":64,"class":42},"Shanghai Argo Biopharmaceutical Co., Ltd.",2,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100594468","a-study-of-body-fat-distribution-and-airway-mechanics-in-healthy-adults-100594468","NCT07019831","A Study of Body Fat Distribution and Airway Mechanics in Healthy Adults","Imaging the Respiratory Effects of Truncal Adiposity in Healthy Subjects","Inclusion Criteria\n\n• Healthy subjects older than 18 years and younger than 80.\n\nExclusion Criteria\n\n* Pre-existing cardiopulmonary disease\n* history of tobacco or ecigarette smoking","80 Years",{"count":75,"type":22},20,[25],"This study investigates how body fat distribution affects airway closure and lung mechanics in healthy adults. Using Electrical Impedance Tomography (EIT), esophageal manometry, and computed tomography (CT), we aim to characterize how varying BMI and fat topography influence regional ventilation and airway collapse in supine and prone positions. Healthy volunteers with a range of BMIs will undergo a 2-hour imaging session with noninvasive and minimally invasive monitoring.",[28],[80,81,82,83,84],"obesity","electrical impedance tomography","computed tomography","esophageal manometry","airway geometry","NOT_YET_RECRUITING","2025-06-16",{"date":88,"type":35},"2025-06-18",{"date":90,"type":22},"2028-01-01",{"date":92,"type":22},"2030-06-30",{"name":94,"class":95},"Maurizio F. Cereda, MD","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":43},"100578956","avocado-and-postprandial-responses-100578956","NCT06818032","Avocado and Postprandial Responses","Acute Avocado Consumption on Postprandial Glycemic and Appetite\u002FSatiety Responses","Inclusion Criteria:\n\n* Biological sex males or females\n* Age 21 to 65 years\n* BMI between 18.5 and 34.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Actively pregnant or lactating women\n* Diagnosis of prediabetes or diabetes (fasting glucose \\>100 mg\u002FdL)\n* Current diagnosis of uncontrolled hypertension (systolic BP: \\>160 mmHg, diastolic BP: \\>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month\n* Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \\>200 mg\u002FdL, fasting triglycerides \\>200 mg\u002FdL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month\n* Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus)\n* History of bariatric or certain other surgeries related to weight control\n* Any medication used to lower blood glucose\u002Fantidiabetic medications \\[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\\] as well as medications affecting weight, appetite\u002Fhunger or gut motility.\n* Smoking or use of other tobacco products (during 6 months prior to the start of the study)\n* Antibiotic use during the intervention or for 3 weeks prior to any treatment period\n* History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets)\n* Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence\n* Body weight loss of \\>10% within the last 6 months prior to study start\n* Unable or unwilling to give informed consent or communicate with study staff\n* Self-report of alcohol or substance abuse within the past 12 months and\u002For current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)\n* Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol\n* Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.","21 Years","65 Years",{"count":106,"type":22},30,[25],"The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.\n\nThe investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:\n\n1. Whole-wheat bread and strawberry jam\n2. Whole-wheat bread, strawberry jam, and avocado\n3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)\n\nParticipants will undergo 3 test periods, each separated by a week. Each test period consists of one day with set meals that the investigators will provide (breakfast, lunch, and dinner), and then the next morning, participants will eat a breakfast meal and have blood drawn several times over 4 hours.",[110,111,112,113,114,115,28,116],"Healthy","Healthy Volunteer","Healthy Volunteers","Healthy Adult","Healthy Male and Female Subjects","Healthy Subjects","Healthy Non-smokers",[118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135],"Persea Americana","blood glucose","blood insulin","adiponectin","leptin","GLP-1","appetite","satiety","glucose tolerance","GIP","ghrelin","Peptide YY (PYY)","glucose metabolism","dietary fats","meal challenge","meal tolerance test","dietary fiber","glycemia","2025-03-24",{"date":138,"type":35},"2025-03-28",{"date":140,"type":22},"2025-03",{"date":142,"type":22},"2026-06",{"name":144,"class":95},"University of Vermont Medical Center",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100572586","profiling-the-variation-of-microbiome-along-the-intestinal-tract-based-on-sampling-capsule-endoscopy-100572586","NCT06735196","Profiling the Variation of Microbiome Along the Intestinal Tract Based on Sampling Capsule Endoscopy","Profiling the Variation of Microbiome Along the Intestinal Tract Based on Sampling Capsule Endoscopy: a Feasibility and Safety Study","Inclusion Criteria:\n\n1. Male or female, age ≥18 years and ≤80 years;\n2. American Society of Anesthesiologists (ASA) physical health risk level 1;\n3. Good overall health, no clinically significant medical history;\n4. No clinically significant signs were found in the physical examination;\n5. For women of fertility, the urine pregnancy test was negative within 7 days after the screening visit, and they were willing to take contraceptive measures throughout the study;\n6. Willing to provide blood samples, stool samples, urine samples, saliva samples, and intestinal fluid samples, and agree that the samples provided will be stored for a long time and used for research purposes.\n7. Agree to avoid strenuous activities during the participation in this clinical trial;\n8. Agree to participate in this clinical trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with digestive tract diseases such as cancer, inflammatory bowel disease, achalasia, esophageal diverticulum, etc.;\n2. Patients who have participated in other clinical trials within three months or are currently participating in other clinical trials;\n3. Patients currently use medication for other diseases or plan to use medication for treatment;\n4. Patients who have used antibiotics within three months;\n5. Patients with known or suspected gastrointestinal obstruction, stenosis, diverticulum, and fistula;\n6. Patients with swallowing disorders;\n7. Pregnant or lactating women or women who plan to become pregnant within 30 days of the visit period;\n8. Patients who are not suitable for surgery or refuse to undergo any abdominal surgery (once the capsule is retained, it cannot be removed by surgery);\n9. Patients with any form of active substance abuse or dependence (including drug or alcohol abuse), any unstable physical or mental illness, any malignant lesions in any location or system, or any chronic disease that the researcher believes may interfere with the study;\n10. The researcher believes any other factors are unsuitable for selection or affect the subject's participation in the study.",{"count":52,"type":22},[25],"Intestinal flora and metabolites are associated with multiple systemic diseases. Current approaches for acquiring information regarding microbiota\u002Fmetabolites have limitations. We aimed to develop a precise sampling capsule endoscopy (SCE) for the convenient, non-invasive, and accurate acquisition of digestive bioinformation for disease diagnosis and evaluation. The SCE was used for sampling jejunum, ileum, and colon content in healthy volunteers. The GI liquid was then used for microbiome profiling and metabolomics profiling. In this study, we aimed to describe the characteristics and functions of key microflora in the whole intestinal microenvironment of healthy volunteers.",[28],[157,158,159,160,161],"sampling capsule endoscopy","gut microorganisms","intestinal fluids","stool","saliva","2024-12-11",{"date":164,"type":35},"2024-12-16",{"date":166,"type":22},"2024-12-30",{"date":168,"type":22},"2026-03-31",{"name":170,"class":95},"Changhai Hospital",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":43},"100564661","effects-of-substance-p-on-headache-induction-in-healthy-individuals-100564661","NCT06632080","Effects of Substance P on Headache Induction in Healthy Individuals","Effects of Substance P on Headache Induction in Healthy Individuals: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder, except for infrequent episodic tensiontype headache\n* Any first-degree relatives with a history of a primary headache disorder, except for infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start",{"count":179,"type":22},21,[25],"Substance P is a signaling molecule that has been implicated in the pathogenesis of headache. This study aims to ascertain whether administration of substance P can induce headache in healthy adults.",[28],[184],"Headache","2024-10-11",{"date":187,"type":35},"2024-10-15",{"date":189,"type":22},"2024-10-14",{"date":191,"type":22},"2025-12-31",{"name":193,"class":95},"Danish Headache Center"]